AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9329422 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical iodine-containing antiseptics (n = 73)
Number of subjects: 128
Study 9329422 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine-containing antiseptics (n = 55)
Number of subjects: 128
Study 9329422 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical iodine-containing antiseptics (n = 24)
Number of subjects: 128
Study 9329422 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (n = 22)
Number of subjects: 128
Study 8204876 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐1 beta (rhIL‐1 beta) at 0.01, 0.02, 0.05 microgram/kg administered by intravenous infusion once a day for 5 doses.
Number of subjects: 17
Study 8204876 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐1 beta (rhIL‐1 beta)
Number of subjects: 17
Study 8204876 — intervention group
Group type: COMPARATOR
Intervention: Historical control (no rhIL‐1 beta)
Number of subjects: 17
Study 3295018 — intervention group
Group type: EXPERIMENTAL
Intervention: Portacaval shunt (PCS)
Number of subjects: 70
Study 3295018 — intervention group
Group type: COMPARATOR
Intervention: Stapler transection (ST)
Number of subjects: 70
Study 3295018 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 70
Study 30350337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal home blood pressure measurement adapted to the chosen bedtime of participants
Number of subjects: 48
Study 30350337 — intervention group
Group type: COMPARATOR
Intervention: Fixed time points (2:00, 3:00, and 4:00 am) for nocturnal home blood pressure measurement
Number of subjects: 48
Study 30350337 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime-based measurement phase
Number of subjects: 48
Study 30350337 — intervention group
Group type: COMPARATOR
Intervention: Fixed-time measurement phase
Number of subjects: 48
Study 30350337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal home BP measurement adapted to the chosen bedtime
Number of subjects: 48
Study 28858553 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine (LB) 133 mg/10 mL
Number of subjects: 150
Study 28858553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 25908603 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab 5 mg/kg
Number of subjects: 387
Study 25908603 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab 10 mg/kg
Number of subjects: 387
Study 25908603 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as standard treatment)
Number of subjects: 387
Study 23681683 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care intervention carried out by LPNs
Number of subjects: 60
Study 23681683 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 21167586 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard method of calculation using median strength value at each stress rate
Number of subjects: 150
Study 21167586 — intervention group
Group type: COMPARATOR
Intervention: Statistical regression method
Number of subjects: 150
Study 18504478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INS)
Number of subjects: 0
Study 17143153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 17143153 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 0
Study 14570788 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Number of subjects: 75
Study 14570788 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal intubation
Number of subjects: 75
Study 14570788 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal intubation plus direct laryngoscopy
Number of subjects: 75
Study 11144071 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitchell's modified method using Dallos polyester fiber prosthesis
Number of subjects: 53
Study 8860730 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz, 100 mu T magnetic field exposure for 9 min
Number of subjects: 100
Study 8860730 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure for 9 min
Number of subjects: 100
Study 1844696 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method using individual subject ratios for assessing bioequivalence
Number of subjects: 0
Study 1844696 — intervention group
Group type: COMPARATOR
Intervention: Logarithmic transformation
Number of subjects: 0
Study 6364297 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Rhinocort) 200 micrograms b.i.d.
Number of subjects: 52
Study 6364297 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (Becotide Nasal) 200 micrograms b.i.d.
Number of subjects: 52
Study 31753900 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic carbohydrate counting (BCC) as add-on to usual dietary care
Number of subjects: 226
Study 31753900 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary care
Number of subjects: 226
Study 29378476 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 112
Study 29378476 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 112
Study 27756405 — intervention group
Group type: EXPERIMENTAL
Intervention: Active binocular treatment (videogame-based) for 6 weeks
Number of subjects: 108
Study 27756405 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 108
Study 27756405 — intervention group
Group type: EXPERIMENTAL
Intervention: Active binocular treatment (videogame-based)
Number of subjects: 108
Study 27756405 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 108
Study 25480528 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable guiding device and DICOM image-reading software assistance for ventriculostomy catheter placement.
Number of subjects: 236
Study 25480528 — intervention group
Group type: COMPARATOR
Intervention: Standard freehand ventriculostomy using anatomical landmarks.
Number of subjects: 236
Study 22705318 — intervention group
Group type: EXPERIMENTAL
Intervention: OptrexActiMist (AM)
Number of subjects: 80
Study 22705318 — intervention group
Group type: COMPARATOR
Intervention: DryEyesMist (DEM)
Number of subjects: 80
Study 22705318 — intervention group
Group type: COMPARATOR
Intervention: TearMist (TM)
Number of subjects: 80
Study 20502361 — intervention group
Group type: EXPERIMENTAL
Intervention: vinorelbine/paclitaxel plus carboplatin
Number of subjects: 150
Study 20502361 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 150
Study 18318948 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% silver vitellinate
Number of subjects: 76
Study 18318948 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline
Number of subjects: 76
Study 15830290 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol intake (highest tertile)
Number of subjects: 109
Study 15830290 — intervention group
Group type: EXPERIMENTAL
Intervention: High vitamin C intake (highest tertile)
Number of subjects: 109
Study 11833019 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulus with mechanical noise
Number of subjects: 25
Study 11833019 — intervention group
Group type: COMPARATOR
Intervention: Vibrotactile stimulus without mechanical noise
Number of subjects: 25
Study 9935018 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 4159
Study 9935018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study 7753966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone 5 mg administered by mouth three times daily for 14 days
Number of subjects: 18
Study 7753966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7753966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone 5 mg
Number of subjects: 18
Study 2113488 — intervention group
Group type: COMPARATOR
Intervention: hMG alone
Number of subjects: 59
Study 2113488 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG with leuprolide acetate (LA)
Number of subjects: 59
Study 2113488 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment cycles pooled
Number of subjects: 59
Study 2113488 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapy with LA
Number of subjects: 59
Study 2113488 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of luteal phase steroids
Number of subjects: 59
Study 365537 — intervention group
Group type: EXPERIMENTAL
Intervention: S-carboxy-methyl-cysteine (S.C.M.C.) 3 g/24h
Number of subjects: 20
Study 365537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30540587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral FSCS simulator training (Group A)
Number of subjects: 20
Study 30540587 — intervention group
Group type: COMPARATOR
Intervention: Skull model training (Group B)
Number of subjects: 20
Study 28052910 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus PC6 wristband
Number of subjects: 60
Study 28052910 — intervention group
Group type: EXPERIMENTAL
Intervention: PC6 wristband alone
Number of subjects: 60
Study 28052910 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture or wristband (Control)
Number of subjects: 60
Study 28052910 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 25299534 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (3 MHz, 1 W/cm)
Number of subjects: 60
Study 25299534 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (3 MHz, 1 W/cm, 1:1 ratio)
Number of subjects: 60
Study 25299534 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 60
Study 23439898 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated reminders
Number of subjects: 1611
Study 23439898 — intervention group
Group type: COMPARATOR
Intervention: No computer-generated reminders (Control)
Number of subjects: 1611
Study 20664387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 6‐month behavioral weight loss program followed by a 12‐month weight maintenance program (n=226)
Number of subjects: 338
Study 20664387 — intervention group
Group type: COMPARATOR
Intervention: Structured education program (control; n=112)
Number of subjects: 338
Study 20664387 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of 5% to less than 10% of body weight
Number of subjects: 338
Study 20664387 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of 10% or more of body weight
Number of subjects: 338
Study 18710905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal non-invasive positive pressure ventilation (NIPPV) + rehabilitation
Number of subjects: 72
Study 18710905 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 72
Study 16882628 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-level high-volt pulsed electrical current (HVPC)
Number of subjects: 20
Study 16882628 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (no electrical current)
Number of subjects: 20
Study 14640857 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed exercise activity
Number of subjects: 28
Study 14640857 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise participants
Number of subjects: 28
Study 11027033 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity in males (15.7%)
Number of subjects: 8957
Study 11027033 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight prevalence
Number of subjects: 8957
Study 11027033 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stature prevalence
Number of subjects: 8957
Study 1536810 — intervention group
Group type: EXPERIMENTAL
Intervention: Included patients in the clinical trial
Number of subjects: 180
Study 1536810 — intervention group
Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 180
Study 1536810 — intervention group
Group type: COMPARATOR
Intervention: Non-reported patients
Number of subjects: 180
Study 1536810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tentative application of exclusion criteria (lower age limit, exclusion of renal failure or low performance status)
Number of subjects: 180
Study 6567953 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission program
Number of subjects: 0
Study 6567953 — intervention group
Group type: EXPERIMENTAL
Intervention: Program given the eve of surgery
Number of subjects: 0
Study 6567953 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31578023 — intervention group
Group type: EXPERIMENTAL
Intervention: OIT with low allergen cookies (LACs)
Number of subjects: 33
Study 31578023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 29463627 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5-50 mg QD)
Number of subjects: 187
Study 29463627 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.1-0.3 mg BID)
Number of subjects: 187
Study 29463627 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 187
Study 29463627 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 187
Study 28078857 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1% administered immediately after the beginning of cardiopulmonary bypass until the end of treatment)
Number of subjects: 60
Study 28078857 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 28078857 — intervention group
Group type: COMPARATOR
Intervention: Control (oxygen mask and physiological saline)
Number of subjects: 60
Study 24375465 — intervention group
Group type: EXPERIMENTAL
Intervention: Defusion protocol (DEF)
Number of subjects: 23
Study 24375465 — intervention group
Group type: COMPARATOR
Intervention: Motivational protocol (MOT)
Number of subjects: 23
Study 24375465 — intervention group
Group type: COMPARATOR
Intervention: Control group (CMOT)
Number of subjects: 23
Study 22424006 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 181
Study 22424006 — intervention group
Group type: EXPERIMENTAL
Intervention: Developer-reported ECG analysis
Number of subjects: 181
Study 22424006 — intervention group
Group type: COMPARATOR
Intervention: Sponsor-reported ECG analysis
Number of subjects: 181
Study 20136971 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine second-look endoscopy with thermal coagulation
Number of subjects: 998
Study 20136971 — intervention group
Group type: COMPARATOR
Intervention: Single endoscopy
Number of subjects: 998
Study 20136971 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection therapy
Number of subjects: 998
Study 17928750 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenoscopic infusion of 90 mL of sodium phosphate (NaP) diluted with 180 mL of water (group EA)
Number of subjects: 0
Study 17928750 — intervention group
Group type: COMPARATOR
Intervention: Orally administered 45 mL of sodium phosphate (NaP) (group OA)
Number of subjects: 0
Study 15603570 — intervention group
Group type: EXPERIMENTAL
Intervention: Episiotomy only for fetal indications
Number of subjects: 146
Study 15603570 — intervention group
Group type: COMPARATOR
Intervention: Episiotomy at a tear presumed to be imminent
Number of subjects: 146
Study 12222651 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization splint
Number of subjects: 36
Study 12222651 — intervention group
Group type: COMPARATOR
Intervention: Control splint
Number of subjects: 36
Study 10915398 — intervention group
Group type: EXPERIMENTAL
Intervention: two 160-mg capsules once daily (OD)
Number of subjects: 100
Study 10915398 — intervention group
Group type: EXPERIMENTAL
Intervention: one 160-mg capsule twice daily (BID)
Number of subjects: 100
Study 8605792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (intermittent intravenous injection, 1.6 +/- 0.1 mg/8 hrs)
Number of subjects: 95
Study 8605792 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (continuous intravenous infusion, 14.4 +/- 1.2 mg/8 hrs)
Number of subjects: 95
Study 8605792 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 95
Study 8605792 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 95
Study 1845581 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counselling and a booklet
Number of subjects: 156
Study 1845581 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 156
Study 6123806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 232
Study 6123806 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and steroids (control)
Number of subjects: 232
Study 30481329 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer sleep onset latency (SOL)
Number of subjects: 42
Study 30481329 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater sensory pain
Number of subjects: 42
Study 30481329 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 42
Study 30381319 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual rehabilitation (12 weeks of physical exercise training, pelvic floor exercise, and psychoeducation)
Number of subjects: 154
Study 30381319 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study 27871846 — intervention group
Group type: COMPARATOR
Intervention: Recovery at room temperature (20 °C)
Number of subjects: 11
Study 27871846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice-water immersion (3 °C, 5 min)
Number of subjects: 11
Study 27021566 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 8726
Study 27021566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8726
Study 24594903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum smoking followed by four days of biochemically verified smoking abstinence
Number of subjects: 147
Study 24594903 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 147
Study 24594903 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 147
Study 22459892 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 9253
Study 22459892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9253
Study 19921223 — intervention group
Group type: EXPERIMENTAL
Intervention: MPE (multimodal preoperative evaluation)
Number of subjects: 225
Study 17552048 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus MTX (3 mg/kg)
Number of subjects: 144
Study 17552048 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus MTX (6 mg/kg)
Number of subjects: 144
Study 17552048 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 144
Study 17552048 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus MTX (3 mg/kg) and (6 mg/kg)
Number of subjects: 144
Study 15726847 — intervention group
Group type: EXPERIMENTAL
Intervention: ITI implants
Number of subjects: 28
Study 15726847 — intervention group
Group type: COMPARATOR
Intervention: Brånemark implants
Number of subjects: 28
Study 12498856 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical apraclonidine 1%
Number of subjects: 61
Study 12498856 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (control)
Number of subjects: 61
Study 12498856 — intervention group
Group type: COMPARATOR
Intervention: Comparison of apraclonidine vs control
Number of subjects: 61
Study 9611008 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with a combination of cis‐diamminedichloroplatinum (CDDP), vincristine, mitomycin C, and peplomycin (POMP)
Number of subjects: 101
Study 9611008 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 101
Study 7704391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalometric indices in OSAS patients
Number of subjects: 16
Study 7704391 — intervention group
Group type: COMPARATOR
Intervention: Cephalometric indices in controls
Number of subjects: 16
Study 1823658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental fear treatment
Number of subjects: 60
Study 1823658 — intervention group
Group type: COMPARATOR
Intervention: Attention effects (waiting list control)
Number of subjects: 60
Study 6160901 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 66
Study 6160901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31835514 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated chess games (computer)
Number of subjects: 27
Study 31835514 — intervention group
Group type: COMPARATOR
Intervention: Real chess games
Number of subjects: 27
Study 28697226 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical proprietary procedural enhancement system (PES) containing a combination of active ingredients including a tripeptide and hexapeptide (TriHex Technology™)
Number of subjects: 0
Study 28697226 — intervention group
Group type: COMPARATOR
Intervention: Basic regimen (Aquaphor™, Cerave™ cleanser, Vanicream™, Alastin Broad Spectrum 30+ Sunscreen)
Number of subjects: 0
Study 25887378 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) programme
Number of subjects: 306
Study 25887378 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 306
Study 24131606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponto Pro's omnidirectional microphone (OM)
Number of subjects: 15
Study 24131606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponto Pro's split directional microphone (SDM)
Number of subjects: 15
Study 24131606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponto Pro's full directional microphone (FDM)
Number of subjects: 15
Study 24131606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponto Pro
Number of subjects: 15
Study 24131606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponto Pro's OM
Number of subjects: 15
Study 24131606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponto Pro's SDM
Number of subjects: 15
Study 24131606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponto Pro's FDM
Number of subjects: 15
Study 21259031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amoxicillin and clavulanic acid (single dose)
Number of subjects: 98
Study 21259031 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo (equal volume, intravenous bolus)
Number of subjects: 98